Erratum: Hybrid Molecule from O2‑(2,4Dinitrophenyl)diazeniumdiolate and Oleanolic Acid: A Glutathione S‑Transferase π‑Activated Nitric Oxide Prodrug with Selective Anti-Human Hepatocellular Carcinoma Activity and Improved Stability (J. Med. Chem. (2013) 56: 11 (4641−4655) DOI: 10.1021/jm400393u);Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: A glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4641-4655

  Fu, Junjie ^a,b   Liu, Ling ^a,c   Huang, Zhangjian ^a,b   Lai, Yisheng ^a,b   Ji, Hui ^a   Peng, Sixun ^a,b   Tian, Jide ^d   Zhang, Yihua ^a,b  

^a China Pharmaceutical University   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PRODRUG; AZO COMPOUND; DRUG DERIVATIVE; GLUTATHIONE; GLUTATHIONE TRANSFERASE P1; ISOENZYME; NITRIC OXIDE DONOR; OLEANOLIC ACID; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DECOMPOSITION; DRUG DESIGN; DRUG STABILITY; DRUG SYNTHESIS; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; NONHUMAN; RAT; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; FEMALE; LD 50; LIVER TUMOR; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZO COMPOUNDS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GLUTATHIONE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; ISOENZYMES; LETHAL DOSE 50; LIVER NEOPLASMS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; NEOPLASM TRANSPLANTATION; NITRIC OXIDE; NITRIC OXIDE DONORS; OLEANOLIC ACID; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84879041449     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.9b01778     Document Type: Erratum

References (35)

1. Denny, W. A. The design of selectively-activated prodrugs for cancer chemotherapy Curr. Pharm. Des. 1996, 2, 281-294 (Pubitemid 126474517)
2. Papot, S.; Tranoy, I.; Tillequin, F.; Florent, J. C.; Gesson, J. P. Design of selectively activated anticancer prodrugs: Elimination and cyclization strategies Curr. Med. Chem. 2002, 2, 155-185 (Pubitemid 34649872)
3. Tanabe, K.; Zhang, Z.; Ito, T.; Hatta, H.; Nishimoto, S. Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments Org. Biomol. Chem. 2007, 5, 3745-3757 (Pubitemid 350115415)
4. Armstrong, R. N. Structure, catalytic mechanism, and evolution of the glutathione transferases Chem. Res. Toxicol. 1997, 10, 2-18 (Pubitemid 27044902)
5. O'Brien, M. L.; Tew, K. D. Glutathione and related enzymes in multidrug resistance Eur. J. Cancer 1996, 32A, 967-978
6. Mahajan, S.; Atkins, W. M. The chemistry and biology of inhibitors and pro-drugs targeted to glutathione S -transferases Cell. Mol. Life Sci. 2005, 62, 1221-1233
7. Zhao, G.; Wang, X. Advance in antitumor agents targeting glutathione- S -transferase Curr. Med. Chem. 2006, 13, 1461-1471
8. Shami, P. J.; Saavedra, J. E.; Wang, L. Y.; Bonifant, C. L.; Diwan, B. A.; Singh, S. V.; Gu, Y.; Fox, S. D.; Buzard, G. S.; Citro, M. L.; Waterhouse, D. J.; Davies, K. M.; Ji, X.; Keefer, L. K. JS-K, a glutathione/glutathione S -transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity Mol. Cancer Ther. 2003, 2, 409-417
9. Fukumura, D.; Kashiwagi, S.; Jain, R. K. The role of nitric oxide in tumour progression Nat. Rev. Cancer 2006, 6, 521-534 (Pubitemid 43980541)
10. Maciag, A. E.; Saavedra, J. E.; Chakrapani, H. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents Anti-Cancer Agents Med. Chem. 2009, 9, 798-803
11. Maciag, A. E.; Nandurdikar, R. S.; Hong, S. Y.; Chakrapani, H.; Diwan, B.; Morris, N. L.; Shami, P. J.; Shiao, Y.-H.; Anderson, L. M.; Keefer, L. K.; Saavedra, J. E. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs J. Med. Chem. 2011, 54, 7751-7758
12. Laschak, M.; Spindler, K. D.; Schrader, A. J.; Hessenauer, A.; Streicher, W.; Schrader, M.; Cronauer, M. V. JS-K, a glutathione/glutathione S -transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells BMC Cancer 2012, 12, 130-139
13. Findlay, V. J.; Townsend, D. M.; Saavedra, J. E.; Buzard, G. S.; Citro, M. L.; Keefer, L. K.; Ji, X.; Tew, K. D. Tumor cell responses to a novel glutathione S -transferase-activated nitric oxide-releasing prodrug Mol. Pharmacol. 2004, 65, 1070-1079 (Pubitemid 38543478)
14. Saavedra, J. E.; Srinivasan, A.; Buzard, G. S.; Davies, K. M.; Waterhouse, D. J.; Inami, K.; Wilde, T. C.; Citro, M. L.; Cuellar, M.; Deschamps, J. R.; Parrish, D.; Shami, P. J.; Findlay, V. J.; Townsend, D. M.; Tew, K. D.; Singh, S.; Jia, L.; Ji, X. H.; Keefer, L. K. PABA/NO as an anticancer lead: Analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity J. Med. Chem. 2006, 49, 1157-1164 (Pubitemid 43221662)
15. Sies, H. Glutathione and its role in cellular functions Free Radical Biol. Med. 1999, 27, 916-921 (Pubitemid 29507465)
16. Chakrapani, H.; Wilde, T. C.; Citro, M. L.; Goodblatt, M. M.; Keefer, L. K.; Saavedra, J. E. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound Bioorg. Med. Chem. 2008, 16, 2657-2664 (Pubitemid 351380916)
17. Cipak, L.; Grausova, L.; Miadokova, E.; Novotny, L.; Rauko, P. Dual activity of triterpenoids: Apoptotic versus antidifferentiation effects Arch. Toxicol. 2006, 80, 429-435 (Pubitemid 43873733)
18. Chen, L.; Zhang, Y.; Kong, X.; Lan, E.; Huang, Z.; Peng, S.; Kaufman, D. L.; Tian, J. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid J. Med. Chem. 2008, 51, 4834-4838
19. Huang, Z.; Zhang, Y.; Zhao, L.; Jing, Y.; Lai, Y.; Zhang, L.; Guo, Q.; Yuan, S.; Zhang, J.; Chen, L.; Peng, S.; Tian, J. Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid Org. Biomol. Chem. 2010, 8, 632-639
20. Huang, Z.; Fu, J.; Liu, L.; Sun, Y.; Lai, Y.; Ji, H.; Knaus, E. E.; Tian, J.; Zhang, Y. Glycosylated diazeniumdiolate-based oleanolic acid derivatives: Synthesis, in vitro and in vivo biological evaluation as anti-human hepatocellular carcinoma agents Org. Biomol. Chem. 2012, 10, 3882-3891
21. Liu, Y.; Hartley, D. P.; Liu, J. Protection against carbon tetrachloride hepatotoxicity by oleanolic acid is not mediated through metallothionein Toxicol. Lett. 1998, 95, 77-85
22. Stockert, R. J.; Morell, A. G. Hepatic binding protein: The galactose-specific receptor of mammalian hepatocytes Hepatology 1983, 3, 750-757 (Pubitemid 13007704)
23. Huang, Z.; Zhang, Y.; Fang, L.; Zhang, Z.; Lai, Y.; Ding, Y.; Cao, F.; Zhang, J.; Peng, S. Nanometre-sized titanium dioxide-catalyzed reactions of nitric oxide with aliphatic cyclic and aromatic amines Chem. Commun. 2009, 1763-1765
24. Kura, T.; Takahashi, Y.; Takayama, T.; Ban, N.; Saito, T.; Kuga, T.; Niitsu, Y. Glutathione S -transferase-π is secreted as a monomer into human plasma by platelets and tumor cells Biochim. Biophys. Acta 1996, 1292, 317-323
25. Tew, K. D.; Dutta, S.; Schultz, M. Inhibitors of glutathione S -transferases as therapeutic agents Adv. Drug Delivery Rev. 1997, 26, 91-104 (Pubitemid 27289527)
26. Cheung, C. S.; Chung, K. K.; Lui, J. C.; Lau, C. P.; Hon, P. M.; Chan, J. Y.; Fung, K. P.; Au, S. W. Leachianone A as a potential anti-cancer drug by induction of apoptosis in human hepatoma HepG2 cells Cancer Lett. 2007, 253, 224-235 (Pubitemid 47017536)
27. McQuade, L. E.; Lippard, S. J. Fluorescent probes to investigate nitric oxide and other reactive nitrogen species in biology Curr. Opin. Chem. Biol. 2010, 14, 43-49
28. Corbiere, C.; Liagre, B.; Terro, F.; Beneytout, J. L. Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis-inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells Cell Res. 2004, 14, 188-196 (Pubitemid 43231816)
29. Kim, Y. M.; Chung, H. T.; Simmons, R. L.; Billiar, T. R. Cellular non-heme iron content is a determinant of nitric oxide-mediated apoptosis, necrosis, and caspase inhibition J. Biol. Chem. 2000, 275, 10954-10961 (Pubitemid 30212732)
30. Zhang, W.; Liu, H. T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells Cell Res. 2002, 12, 9-18 (Pubitemid 135708299)
31. Wagner, E. F.; Nebreda, A. R. Signal integration by JNK and p38 MAPK pathways in cancer development Nat. Rev. Cancer 2009, 9, 537-549
32. Son, Y.; Cheong, Y. K.; Kim, N. H.; Chung, H. T.; Kang, D. G.; Pae, H. O. Mitogen-activated protein kinases and reactive oxygen species: How can ROS activate MAPK pathways? J. Signal Transduction 2011, 2011, 792639
33. Nandurdikar, R. S.; Maciag, A. E.; Holland, R. J.; Cao, Z.; Shami, P. J.; Anderson, L. M.; Keefer, L. K.; Saavedra, J. E. Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs Bioorg. Med. Chem. 2012, 20, 3094-3099
34. Wu, X.; Tang, X.; Xian, M.; Wang, P. G. Glycosylated diazeniumdiolates: A novel class of enzyme-activated nitric oxide donors Tetrahedron Lett. 2001, 42, 3779-3782 (Pubitemid 32493751)
35. 2-aryl diazeniumdiolates in vitro and in vivo J. Med. Chem. 2006, 49, 4356-4366 Jiangsu Province China Pharmaceutical University